In:
Journal of Pediatric Hematology/Oncology, Ovid Technologies (Wolters Kluwer Health), Vol. 44, No. 3 ( 2022-04), p. e637-e642
Abstract:
Desmoplastic small round cell tumor (DSRCT) is an aggressive sarcoma occurring in the young, teenager, and adult populations. The aim of this study is to compare initial tumor presentation, therapeutic management and scalability between pediatric and adult DSRCT patients and investigate the possibility of specific therapeutic approaches. A multicenter retrospective study of 81 Franco-Belgian medical files with DSRCT harboring Ewing sarcoma-Wilm tumor transcript was made. Median age was 17 years (3 to 58) with 42 children (13.5 y [3;17]) and 39 adults (28 y [18;58] ). No significant differences were found between the 2 groups regarding initial symptoms and metastasis at diagnosis. The therapeutic approaches were similar for both groups: use of neoadjuvant chemotherapy (78.6% vs. 79.5%, P =1), primary surgery (71.4% vs. 69.2%, P =0.73), adjuvant chemotherapy (54.8% vs. 61.5%, P =0.99), radiotherapy (23.8% and 10.3%, P =0.11) and intraperitoneal chemotherapy (14.3% vs. 2.6%; P =0.11). Median time to recurrence was 12 versus 18 months ( P =0.13). Overall survival at 2 years and recurrence free were 46.4% versus 60.1% ( P =0.83) and 14.3% versus 16%, respectively ( P =0.16). Clinical presentation, initial therapeutics and outcome of DSRCT are equivalent suggesting that similar management should be considered for children and adults with DSRCT.
Type of Medium:
Online Resource
ISSN:
1077-4114
DOI:
10.1097/MPH.0000000000002252
Language:
English
Publisher:
Ovid Technologies (Wolters Kluwer Health)
Publication Date:
2022
detail.hit.zdb_id:
2047125-7
Permalink
